About: Fate Therapeutics, Inc., a clinical-stage biopharmaceutical company, develops programmed cellular immunotherapies for cancer and immune disorders in the United States and internationally. The company's chimeric antigen receptor (CAR)-targeted NK and T-cell product candidates include FT836 which is in preclinical stage for multiple tumor types; and FT522, to treat B-cell Lymphoma and autoimmunity. Its CAR T-cell programs include FT819 to treat systemic lupus erythematosus, FT839, to treat complex autoimmune diseases; and FT825 to treat solid tumors. It has a collaboration and option agreement with Ono Pharmaceutical Co. Ltd. for the development and commercialization of off-the-shelf, iPSC-derived CAR T-cell product candidates for the treatment of solid tumors. The company was incorporated in 2007 and is headquartered in San Diego, California.
Sector: Healthcare
Industry: Biotechnology
Latest price: $2.05 (+0.25%)
FATE NASDAQ Fate Therapeutics Inc
Fate Therapeutics Inc share price
FATE price activity
Last Price
$2.070
Change (24hr)
0.03 USD (1.47%)
Volume
343.34K
Volume (4w avg)
-
Open
$2.05
Day Range
$2.03 - $2.10
Previous Close
$2.04
Last Trade
04 Nov, 4:58 pm GMT+0
Delayed
04 Nov, 4:58 pm GMT+0
FATE price performance
Delayed
04 Nov, 4:58 pm GMT+0
FATE details
FATE Market Signals